Capital Fund Management S.A. Sells 168,779 Shares of Haleon plc (NYSE:HLN)

Capital Fund Management S.A. lowered its stake in Haleon plc (NYSE:HLN - Free Report) by 75.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 54,421 shares of the company's stock after selling 168,779 shares during the period. Capital Fund Management S.A.'s holdings in Haleon were worth $519,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Procyon Advisors LLC boosted its position in Haleon by 41.3% in the 4th quarter. Procyon Advisors LLC now owns 230,240 shares of the company's stock valued at $2,196,000 after buying an additional 67,329 shares during the last quarter. Jane Street Group LLC boosted its holdings in Haleon by 1,689.4% in the third quarter. Jane Street Group LLC now owns 264,977 shares of the company's stock valued at $2,803,000 after acquiring an additional 250,169 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Haleon by 29.8% in the fourth quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company's stock valued at $19,758,000 after acquiring an additional 475,934 shares during the last quarter. JPMorgan Chase & Co. increased its position in Haleon by 25.3% in the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company's stock worth $53,791,000 after purchasing an additional 1,026,939 shares during the period. Finally, SeaCrest Wealth Management LLC bought a new stake in Haleon during the 4th quarter worth about $102,000. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Trading Up 2.5 %

NYSE:HLN traded up $0.26 during trading hours on Tuesday, hitting $10.45. The stock had a trading volume of 17,040,385 shares, compared to its average volume of 7,207,818. The business's 50 day moving average is $10.11 and its 200-day moving average is $9.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The company has a market cap of $47.17 billion, a price-to-earnings ratio of 30.72, a P/E/G ratio of 2.82 and a beta of 0.24. Haleon plc has a one year low of $8.12 and a one year high of $10.80.

Haleon (NYSE:HLN - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The business had revenue of $3.54 billion during the quarter, compared to analysts' expectations of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. Sell-side analysts anticipate that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The firm also recently declared a -- dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be given a dividend of $0.1166 per share. The ex-dividend date is Friday, April 25th. This represents a dividend yield of 1.6%. This is a positive change from Haleon's previous -- dividend of $0.05. Haleon's dividend payout ratio (DPR) is currently 58.97%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on HLN. Morgan Stanley lowered shares of Haleon from an "overweight" rating to an "equal weight" rating in a research note on Friday, January 10th. Sanford C. Bernstein cut shares of Haleon from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 8th. Hsbc Global Res cut shares of Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Finally, HSBC reiterated a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Six research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.